3D Medicines Balance Sheet Health
Financial Health criteria checks 5/6
3D Medicines has a total shareholder equity of CN¥772.9M and total debt of CN¥229.7M, which brings its debt-to-equity ratio to 29.7%. Its total assets and total liabilities are CN¥1.3B and CN¥490.7M respectively.
Key information
29.7%
Debt to equity ratio
CN¥229.75m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥652.82m |
| Equity | CN¥772.87m |
| Total liabilities | CN¥490.67m |
| Total assets | CN¥1.26b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1244's short term assets (CN¥1.0B) exceed its short term liabilities (CN¥401.9M).
Long Term Liabilities: 1244's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥88.8M).
Debt to Equity History and Analysis
Debt Level: 1244 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 1244's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1244 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 1244 has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 16.3% each year.